Cargando…

Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study

BACKGROUND: Bedaquiline (BDQ) is a novel agent approved for use in combination treatment of multi-drug resistant tuberculosis (MDR-TB). We sought to determine BDQ epidemiological cut-off values (ECVs), define and assess interpretive criteria against putative resistance associated variants (RAVs), mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ismail, Nazir A., Omar, Shaheed V., Joseph, Lavania, Govender, Netricia, Blows, Linsay, Ismail, Farzana, Koornhof, Hendrik, Dreyer, Andries W., Kaniga, Koné, Ndjeka, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835552/ https://www.ncbi.nlm.nih.gov/pubmed/29337135 http://dx.doi.org/10.1016/j.ebiom.2018.01.005

Ejemplares similares

Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing
por: Ismail, Nazir A., et al.
Publicado: (2020)

Drug resistant tuberculosis in Africa: Current status, gaps and opportunities
por: Ismail, Nazir, et al.
Publicado: (2018)

Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study
por: Kaniga, Koné, et al.
Publicado: (2020)

Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis
por: Pai, Helen, et al.
Publicado: (2022)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

Whole genome sequencing for drug resistance determination in Mycobacterium tuberculosis
por: Omar, Shaheed V., et al.
Publicado: (2019)

A Novel Molecular Strategy for Surveillance of Multidrug Resistant Tuberculosis in High Burden Settings
por: Said, Halima M., et al.
Publicado: (2016)

Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa
por: Rukasha, Ivy, et al.
Publicado: (2016)

Distribution and Clonality of drug-resistant tuberculosis in South Africa
por: Said, Halima, et al.
Publicado: (2021)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Draft Genome Sequence of Mycobacterium peregrinum Isolated from an HIV-Positive Patient in South Africa
por: Omar, Shaheed V., et al.
Publicado: (2017)

Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis
por: Ismail, N., et al.
Publicado: (2018)

Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study
por: Brust, James C M, et al.
Publicado: (2021)

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era
por: Beckert, Patrick, et al.
Publicado: (2020)

Improved Synthesis and Isolation of Bedaquiline
por: Lubanyana, Hlengekile, et al.
Publicado: (2020)

Whole-Genome Sequence of a Mycobacterium goodii Isolate from a Pediatric Patient in South Africa
por: Allam, Mushal, et al.
Publicado: (2018)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Correction to “Improved Synthesis and Isolation of Bedaquiline”
por: Lubanyana, Hlengekile, et al.
Publicado: (2020)

Determining the risk-factors for molecular clustering of drug-resistant tuberculosis in South Africa
por: Said, Halima, et al.
Publicado: (2023)

Prior Pulmonary Tuberculosis Is a Risk Factor for Asymptomatic Cryptococcal Antigenemia in a Cohort of Adults With Advanced Human Immunodeficiency Virus Disease
por: Wake, Rachel M, et al.
Publicado: (2022)

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Moe, S., et al.
Publicado: (2023)

Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis
por: Jha, Swati, et al.
Publicado: (2016)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Feasibility of using postal and web-based surveys to estimate the prevalence of tuberculosis among health care workers in South Africa
por: Manana, Pinky N., et al.
Publicado: (2018)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
por: Wu, Sheng-Han, et al.
Publicado: (2021)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Treatment Outcome of Tubercular Uveitis in a High TB and HIV Setting: A Prospective Cohort Study
por: Alli, Hassan Dawood, et al.
Publicado: (2021)

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
por: Snobre, J., et al.
Publicado: (2023)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis
por: Gaida, Razia, et al.
Publicado: (2020)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
por: Putra, Oki Nugraha, et al.
Publicado: (2021)

Emergence of bedaquiline resistance in a high tuberculosis burden country
por: Chesov, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5grqa7ue98hit38n58e82b247a